Search clinical trials for: VGR-R01

Total 3919 results

Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.

Active, not recruiting

ANC-501 in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Dr. Anupam Sehgal
Taysha Gene Therapies, Inc.; GlycoNet

Active, not recruiting

First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis

Infantile GM2 Gangliosidosis (Disorder)

Canada
Innovo Therapeutics, Inc.

Completed

First in Human, Single Ascending Dose Study

Ulcerative Colitis

Korea, Republic of
Invenux, LLC
State University of New York - Downstate Medical Center

Active, not recruiting

Dose-Escalation Study of SCD-101 in Sickle Cell Disease

Sickle Cell Disease | Sickle-Beta Zero Thalassemia

United States
Ossium Health, Inc.

Withdrawn

Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)

GVHD,Acute
Amgen

Withdrawn

A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ProxiMMity-1)

Relapsed/Refractory Multiple Myeloma
Flame Biosciences

Withdrawn

FL- 101 Study in Non-Metastatic MIBC

Muscle Invasive Bladder Carcinoma
Adicet Bio, Inc

Enrolling by invitation

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma

United States
Abeona Therapeutics, Inc

Terminated

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

Mucopolysaccharidosis III-B

United States, Germany, France
Lumen Bioscience, Inc.

Completed

Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies

C. Diff. Infections

Australia
Forte Biosciences, Inc.

Terminated

Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study

Atopic Dermatitis

United States
Pfizer

Completed

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

Reduction in Hypertrophic Skin Scarring

United States
Stargazer Pharmaceuticals, Inc.

Completed

Study of STG-001 in Subjects With Stargardt Disease

Stargardt Disease-1

United States
AL-S Pharma

Unknown

A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Canada
Otonomy, Inc.

Completed

Open-Label Study of OTO-201 for Treatment of AOMT

Acute Otitis Media | AOMT

United States
United BioSource, LLC
AveXis, Inc.

Approved for marketing

AveXis Managed Access Program Cohort for Access to AVXS-101

Spinal Muscular Atrophy

United States
ADC Therapeutics S.A.

Terminated

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

Advanced Solid Tumors

United States
Benitec BioPharma Ltd

Completed

A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

Australia, Russian Federation
Viscofan
Ministerio de Ciencia e Innovación, Spain

Unknown

First in Humans to Evaluate Collagen Patches With Stem Cells in Patients With Ischemic Left Ventricular Dysfunction (CARDIOMESH)

Heart Failure With Reduced Ejection Fraction

Spain
BioMarin Pharmaceutical

Terminated

BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

Late-onset Pompe Disease

United States, United Kingdom, Germany, France, Italy, Portugal, Belgium, Netherlands
Curis, Inc.

Terminated

Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients

Cancer

United States
Minerva Neurosciences

Completed

A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects

Healthy Subjects

Ireland
LYSOGENE

Completed

Long-term Follow-up of Sanfilippo Type A Patients Treated by Intracerebral SAF-301 Gene Therapy

Mucopolysaccharidosis Type III A | Sanfilippo Disease Type A

France
Orion Corporation, Orion Pharma
Endo Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Prostate Cancer

United States, United Kingdom, Finland, France, Czech Republic, Estonia
LYSOGENE

Completed

Intracerebral Gene Therapy for Sanfilippo Type A Syndrome

Mucopolysaccharidosis Type III A | Sanfilippo Disease Type A

France
Healthpoint

Completed

Cumulative Irritation Potential of 828 Ointment

Healthy Volunteers

United States
Cerenis Therapeutics, SA

Completed

Exploratory Study of Plaque Regression (EXPRESS)

Heterozygous Familial Hypercholesterolemia

Canada
Healthpoint

Terminated

Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage

Skin Abnormalities

United States
Norgine

Completed

A Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101

Postoperative Ileus

United Kingdom
M.D. Anderson Cancer Center
Alaunos Therapeutics

Completed

Phase I Trial of ZIO-101 in Patients With Solid Tumors

Solid Tumors

United States
C.B. Fleet Company, Inc.

Completed

Efficacy Study of Bowel Preparation Before Colonoscopy

Bowel Cleansing Prior to Colonoscopy

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma

Lymphoma | Advanced Solid Tumors

United States
Danube Pharmaceuticals, Inc.

Completed

Safety, Efficacy, and Pharmacokinetic Profile of DNB-001 in Subjects With Elevated Intraocular Pressure (DNB-001)

Ocular Hypertension | Glaucoma | Elevated IOP

United Kingdom
Celgene Corporation

Terminated

Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Myeloid Leukemia

United States
Bioray Laboratories
Xiangya Hospital of Central South University; First Affiliated Hospital of... and other collaborators

Enrolling by invitation

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

Beta-Thalassemia

China
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Completed

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

Ulcerative Colitis

United States
TG Therapeutics, Inc.

Terminated

A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304

Chronic Lymphocytic Leukemia

United States, Poland, Italy, United Kingdom
GeneOne Life Science, Inc.
Inovio Pharmaceuticals

Completed

Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (VGX-6150-01)

Hepatitis C, Chronic

Korea, Republic of
Dynavax Technologies Corporation
Merck Sharp & Dohme LLC

Terminated

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Metastatic Melanoma | Head Neck Cancer

United States, Germany, New Zealand, Australia
Scioderm, Inc.
Food and Drug Administration (FDA); Amicus Therapeutics

Terminated

Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

United States
Coordination Pharmaceuticals, Inc.

Recruiting

Phase I Study of RiMO-401 With Radiation in Advanced Tumors

Advanced Solid Tumor | Intratumoral Injection

United States
University of Kentucky
Inflammasome Therapeutics

Recruiting

Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy (K8 for GA)

Age-Related Macular Degeneration | Geographic Atrophy

United States
AL-S Pharma

Recruiting

A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Korea, Republic of, United States, Canada, Germany, Sweden, Belgium
Shandong TheraWisdom Biopharma Co., Ltd.

Recruiting

Safety and Tolerability of TWP-201 in Healthy Female Subjects

Infertility

China
Onconova Therapeutics, Inc.

Recruiting

Study of ON 123300 in Patients With Advanced Cancer

Solid Tumors, Adult

United States
Coordination Pharmaceuticals, Inc.
University of Chicago

Recruiting

Phase I Study of RiMO-301 With Radiation in Advanced Tumors

Advanced Tumors

United States
Alzheon Inc.

Enrolling by invitation

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects (APOLLOE4-LTE)

Early Alzheimer's Disease

United States, Spain, Canada, Netherlands, Czechia, United Kingdom, France, Germany, Iceland
Gustave Roussy, Cancer Campus, Grand Paris

Active, not recruiting

A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer (ODENZA)

Metastatic Castrate-resistant Prostate (CRPC) Cancer

France
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

Moderate-to-severe Atopic Dermatitis

China
QurAlis Corporation

Completed

A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants

Healthy Volunteers

Netherlands

Search clinical trials for: VGR-R01

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations